Roivant Sciences, Inc.
156 articles about Roivant Sciences, Inc.
-
A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.
-
Roivant has chalked up a mid-stage victory for its Pfizer-partnered dual TYK2/JAK1 inhibitor, setting it up to start a Phase III trial in non-anterior non-infectious uveitis this year.
-
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
4/2/2024
Roivant and Priovant Therapeutics announced positive results from the Phase 2 study evaluating brepocitinib in non-anterior non-infectious uveitis, showing the strongest efficacy data in NIU observed to date.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
Roivant Sciences will wind down operations for Hemavant, which was formed two years ago to advance RVT-2001 as a potential first-in-class treatment for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes.
-
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
2/13/2024
Roivant reported its financial results for the third quarter ended December 31, 2023, and provided a business update.
-
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
1/30/2024
Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, February 13, 2024, to report its financial results for the third quarter ended December 31, 2023, and provide a business update.
-
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
11/27/2023
Roivant (Nasdaq: ROIV) and Priovant today announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at Week 52. Priovant plans to disclose the study data at a future date.
-
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
11/13/2023
Roivant reported its financial results for the second quarter ended September 30, 2023, and provided an update on the business.
-
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
10/30/2023
Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business update.
-
The Swiss drugmaker gains rights to RVT-3101 in the U.S. and Japan. Telavant was formed in late 2022 by Roivant and Pfizer, which had a 25% stake in the venture and retains rights to the antibody in other countries.
-
Shares were up over 60% in premarket trading on news that the company’s anti-FcRn antibody exhibited dose-dependent reductions in IgG levels, drivers of inflammation in many autoimmune diseases.
-
Roivant Announces Completion of Redemption of its Outstanding Warrants - September 11, 2023
9/11/2023
Roivant announced that it completed the redemption of its outstanding public warrants and private placement warrants that remained outstanding following 5:00 p.m. New York City Time on September 1, 2023 for a redemption price of $0.10 per Warrant.
-
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
8/14/2023
Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2023, and provided an update on the business.
-
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
8/3/2023
Roivant announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 14, 2023, to report its financial results for the quarter ended June 30, 2023, and provide a business update.
-
Roivant Announces Redemption of Outstanding Warrants - August 02, 2023
8/2/2023
Roivant announced that it will redeem all of its outstanding public warrants and private placement warrants to purchase Roivant’s common shares pursuant to its Warrant Agreement dated September 30, 2021 with Equiniti Trust Company, LLC as successor warrant agent, that remain outstanding following 5:00 p.m. New York City Time on September 1, 2023 for a redemption price of $0.10 per Warrant.
-
This week: Cancer license deals from J&J and BeiGene, a potential $7B acquisition by Roche and confirmed $1.9B Lilly buy, EU fine for Illumina, and more legal challenges to the Inflation Reduction Act
-
The Swiss pharma is in talks to acquire Roivant Sciences' RVT-3101, an anti-TL1A antibody that recently showed promising results in a Phase IIb ulcerative colitis trial, reports The Wall Street Journal.
-
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
6/28/2023
Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.
-
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
6/28/2023
Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.